The most modified of these four trial therapies is FT576, which is an iPS-NK therapy engineered with a B cell maturation antigen (BCMA) CAR for use in patients with multiple myeloma (MM; Clinicatrials.gov Identifier NCT05182073). This evidence concerns the gene TNFRSF17 and AL amyloidosis.